Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

The RhoJ-BAD signaling network: An Achilles' heel for BRAF mutant melanomas.

Ruiz R, Jahid S, Harris M, Marzese DM, Espitia F, Vasudeva P, Chen CF, de Feraudy S, Wu J, Gillen DL, Krasieva TB, Tromberg BJ, Pavan WJ, Hoon DS, Ganesan AK.

PLoS Genet. 2017 Jul 28;13(7):e1006913. doi: 10.1371/journal.pgen.1006913. eCollection 2017 Jul.

2.

Aberrant expression of kallikrein-related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion.

Delaunay T, Deschamps L, Haddada M, Walker F, Soosaipillai A, Soualmia F, El Amri C, Diamandis EP, Brattsand M, Magdolen V, Darmoul D.

Mol Oncol. 2017 Oct;11(10):1330-1347. doi: 10.1002/1878-0261.12103. Epub 2017 Aug 11.

3.

MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line.

Rinner B, Gandolfi G, Meditz K, Frisch MT, Wagner K, Ciarrocchi A, Torricelli F, Koivuniemi R, Niklander J, Liegl-Atzwanger B, Lohberger B, Heitzer E, Ghaffari-Tabrizi-Wizsy N, Zweytick D, Zalaudek I.

Sci Rep. 2017 May 18;7(1):2098. doi: 10.1038/s41598-017-02197-y.

4.

RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.

Dorard C, Estrada C, Barbotin C, Larcher M, Garancher A, Leloup J, Beermann F, Baccarini M, Pouponnot C, Larue L, Eychène A, Druillennec S.

Nat Commun. 2017 May 12;8:15262. doi: 10.1038/ncomms15262.

5.

NMR metabolic fingerprints of murine melanocyte and melanoma cell lines: application to biomarker discovery.

Santana-Filho AP, Jacomasso T, Riter DS, Barison A, Iacomini M, Winnischofer SM, Sassaki GL.

Sci Rep. 2017 Feb 15;7:42324. doi: 10.1038/srep42324.

6.

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.

Kim A, Cohen MS.

Expert Opin Drug Discov. 2016 Sep;11(9):907-16. doi: 10.1080/17460441.2016.1201057. Epub 2016 Jun 23. Review.

7.

The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer.

Wellbrock C, Arozarena I.

Front Cell Dev Biol. 2016 Apr 27;4:33. doi: 10.3389/fcell.2016.00033. eCollection 2016. Review.

8.

Searching for the Chokehold of NRAS Mutant Melanoma.

Posch C, Vujic I, Monshi B, Sanlorenzo M, Weihsengruber F, Rappersberger K, Ortiz-Urda S.

J Invest Dermatol. 2016 Jul;136(7):1330-1336. doi: 10.1016/j.jid.2016.03.006. Epub 2016 May 7. Review.

9.

MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.

Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, Davies MA, Berger AC, Aplin AE.

J Invest Dermatol. 2016 Feb;136(2):453-63. doi: 10.1016/j.jid.2015.11.012. Epub 2015 Nov 20.

10.

Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Bhargava A, Anant M, Mack H; Reproducibility Project: Cancer Biology; Reproducibility Project Cancer Biology.

Elife. 2016 Feb 17;5. pii: e11999. doi: 10.7554/eLife.11999.

11.

Phytochemicals for the Management of Melanoma.

Pal HC, Hunt KM, Diamond A, Elmets CA, Afaq F.

Mini Rev Med Chem. 2016;16(12):953-79. Review. Erratum in: Mini Rev Med Chem. 2017;17 (15):1500.

12.

Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment.

Hassan M, Selimovic D, Hannig M, Haikel Y, Brodell RT, Megahed M.

World J Exp Med. 2015 Nov 20;5(4):206-17. doi: 10.5493/wjem.v5.i4.206. eCollection 2015 Nov 20. Review.

13.
14.

Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.

Whittaker SR, Cowley GS, Wagner S, Luo F, Root DE, Garraway LA.

Mol Cancer Ther. 2015 Dec;14(12):2700-11. doi: 10.1158/1535-7163.MCT-15-0136-T. Epub 2015 Sep 8.

15.

Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway.

Kardos GR, Wastyk HC, Robertson GP.

Mol Cancer Res. 2015 Oct;13(10):1408-20. doi: 10.1158/1541-7786.MCR-15-0048. Epub 2015 Jun 16.

16.

Activation of β2-adrenergic receptor by (R,R')-4'-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells.

Wnorowski A, Sadowska M, Paul RK, Singh NS, Boguszewska-Czubara A, Jimenez L, Abdelmohsen K, Toll L, Jozwiak K, Bernier M, Wainer IW.

Cell Signal. 2015 May;27(5):997-1007. doi: 10.1016/j.cellsig.2015.02.012. Epub 2015 Feb 20.

17.

The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.

Wada M, Horinaka M, Yamazaki T, Katoh N, Sakai T.

PLoS One. 2014 Nov 25;9(11):e113217. doi: 10.1371/journal.pone.0113217. eCollection 2014.

18.

Investigation of cAMP microdomains as a path to novel cancer diagnostics.

Desman G, Waintraub C, Zippin JH.

Biochim Biophys Acta. 2014 Dec;1842(12 Pt B):2636-45. doi: 10.1016/j.bbadis.2014.08.016. Epub 2014 Sep 7. Review.

19.

Beyond BRAF: where next for melanoma therapy?

Fedorenko IV, Gibney GT, Sondak VK, Smalley KS.

Br J Cancer. 2015 Jan 20;112(2):217-26. doi: 10.1038/bjc.2014.476. Epub 2014 Sep 2. Review.

20.

No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.

Girotti MR, Saturno G, Lorigan P, Marais R.

Mol Oncol. 2014 Sep 12;8(6):1140-58. doi: 10.1016/j.molonc.2014.07.027. Epub 2014 Aug 15. Review.

Supplemental Content

Support Center